Glycopyrronium (PT001) vs Tiotropium bromide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Muscarinic acetylcholine receptor (M3) · full Asthma pipeline
Glycopyrronium (PT001)
Developed by AstraZeneca
NCT03358147 · Phase 2/3 · completed
The study was randomized and quadruple-masked for the placebo comparison, included 1,077 participants, and used placebo and open-label active comparators. Its primary measure was a lung-function surrogate rather than a hard clinical outcome, and although the reported PT001 values were numerically higher than placebo, whether the prespecified primary comparison was statistically significant is not stated.
Next expected readout: May 2029 · NCT07525375 (registry estimate)
Reported efficacy
Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): Change From Baseline in Forced Expiratory Volume in 1 Second (FEV1) Area Under the Curve From 0 to 4 Hours (AUC0-4) (Week 24): GP MDI 28.8 μg 0.294 Liter (95% CI 0.248 to 0.341) | GP MDI 14.4 μg 0.284 Liter (95% CI 0.238 to 0.331) | GP MDI 7.2 μg 0.308 Liter (95% CI 0.263 to 0.354) vs Placebo MDI 0.24 Liter (95% CI 0.194 to 0.287) | Spiriva Respimat 2.5 μg 0.347 Liter (95% CI 0.282 to 0.412) (unclear)
Result source: NCT03358147
Tiotropium bromide
Marketed by Boehringer Ingelheim
NCT00772538 · Phase 3 · completed
The trial randomized 459 participants to double-blind tiotropium or matching placebo, with 237 receiving tiotropium and 222 placebo. The primary comparisons favored tiotropium, including significant improvements in peak and trough FEV1 at 24 weeks and a significant reduction in time to first severe asthma exacerbation in the pooled twin-trial analysis.
Next expected readout: January 2027 · NCT06679465 (registry estimate)
Reported efficacy
Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Trough FEV1 Response Determined After a Treatment Period of 24 Weeks. (Baseline and 24 weeks); Time to First Severe Asthma Exacerbation During the 48-week Treatment of the Pooled Data From the Two Twin Trials 205.416 (NCT00772538) and the Present 205.417 (NCT00776984). (48 weeks): Peak Forced Expiratory Volume in 1 Second (FEV1) Response Within 3 Hours Post Dosing (0-3h) After a Treatment Period of 24 Weeks. (Baseline and 24 weeks): Tio R5 0.401 Liter (Standard Error 0.025) vs Placebo 0.315 Liter (Standard Error 0.026) (met)
Result source: NCT00772538
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Glycopyrronium (PT001) | Tiotropium bromide |
|---|---|---|
| Severe exacerbations, annualised rate | —Not reported | —Not reported |
| Trough FEV1, change | 0.1 vs 0.1±0 vs placeboNCT033581472 other results
| 0.1 vs -0.0+0.2 vs placeboNCT0117280840 other results
|
| ACQ-5, change | -0.9 vs -0.9+0.1 vs placeboNCT033581472 other results
| —Not reported |
| OCS dose reduction | —Not reported | —Not reported |
Severe exacerbations, annualised rate
- Glycopyrronium (PT001)
- —Not reported
- Tiotropium bromide
- —Not reported
Trough FEV1, change
- Glycopyrronium (PT001)
- 0.1 vs 0.1±0 vs placeboNCT03358147
2 other results
- 0.1 vs 0.1 NCT03358147
- 0.1 vs 0.1 NCT03358147
- Tiotropium bromide
- 0.1 vs -0.0+0.2 vs placeboNCT01172808
40 other results
- 0.2 vs -0.0 NCT01172821
- 0.1 vs 0.1 NCT00772538
- 0.1 vs -0.0 NCT01172808
- 0.1 vs -0.0 NCT01172821
- 0.2 vs 0.0 NCT00776984
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.3 vs 0.3 NCT01634139
- 0.1 vs 0.1 NCT01340209
- 0.3 vs 0.2 NCT01634139
- 0.4 vs 0.3 NCT01257230
- 0.2 vs 0.1 NCT01634152
- 0.3 vs 0.2 NCT01277523
- 0.1 vs 0.0 NCT01316380
- 0.1 vs 0.1 NCT00772538
- 0.4 vs 0.3 NCT01634139
- 0.2 vs 0.1 NCT00776984
- 0.2 vs 0.1 NCT01340209
- 0.2 vs -0.0 NCT02573155
- 0.1 vs -0.0 NCT02573155
- 0.5 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- 0.3 vs -0.0 NCT02573155
- 0.2 vs -0.0 NCT02573155
- -0.0 vs -0.0 NCT02573155
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.3 vs 0.1 NCT01152450
- 0.4 vs 0.3 NCT01122680
- 0.3 vs 0.1 NCT01152450
- 0.2 vs 0.1 NCT01383499
- 0.1 vs 0.0 NCT01233284
- 0.4 vs 0.3 NCT01122680
ACQ-5, change
- Glycopyrronium (PT001)
- -0.9 vs -0.9+0.1 vs placeboNCT03358147
2 other results
- -0.8 vs -0.9 NCT03358147
- -1.0 vs -0.9 NCT03358147
- Tiotropium bromide
- —Not reported
OCS dose reduction
- Glycopyrronium (PT001)
- —Not reported
- Tiotropium bromide
- —Not reported
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. Glycopyrronium (PT001): 5 of 5 rows · Tiotropium bromide: 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Glycopyrronium (PT001) | Tiotropium bromide Rows use multiple source trials |
|---|---|---|
| AQLQ absolute change · score | 0.89 vs 0.96 placebo score @ 24wk28.8 μga,b,c,d,e NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more doses0.9 vs 0.96 placebo score @ 24wk14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 1.02 vs 0.96 placebo score @ 24wk7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 0.15 vs 0.28 LABA + 1xICS score @ 14wkb,c,d,e NCT00565266 · Phase 3 · combination · Asthma · phase 3 |
| Dropout rate | 14.5%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results16.3%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 14.2%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 11%5 µg/dayf NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 4.4%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 3.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 8%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 4.4%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 7%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 7%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 8.7%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 4.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 5.1%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 3.2%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 1.9%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 9.6%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | 1.3%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results3.8%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.9%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 2.5%5 µg/dayf NCT00772538 · Phase 3 show 39 more results— NCT00565266 · Phase 3 · combination · Asthma · phase 3 —2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on —5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.5%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 0%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 0.9%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.8%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.5%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 3%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 0.8%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 1.3%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.9%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence —5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence —2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on —2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence —2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence —2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence —900 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —400 μg NCT02573155 · Phase 1 · registry result, not featured evidence —200 μg NCT02573155 · Phase 1 · registry result, not featured evidence —50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 3.8%28.8 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results2.9%14.4 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 2.5%7.2 μg NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 7.6%5 µg/dayf NCT00772538 · Phase 3 show 39 more results1.5% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.2%2.5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 0.7%5 mcg NCT01634139 · Phase 3 · registry result, not featured evidence · add on 1.5%2.5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 3.1%5 mcg NCT01634152 · Phase 3 · registry result, not featured evidence · add on 1.6%2.5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 2.2%5 mcg NCT01257230 · Phase 3 · registry result, not featured evidence 0.8%2.5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 1.5%5 μg NCT01277523 · Phase 3 · registry result, not featured evidence · add on 3.5%2.5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 3.5%5 µg once daily NCT01340209 · Phase 3 · registry result, not featured evidence 1.9%2.5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 1.5%5 mcg once daily NCT01172808 · Phase 3 · registry result, not featured evidence 2.7%2.5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 2.8%5 mcg once daily NCT01172821 · Phase 3 · registry result, not featured evidence 0%2.5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 0.6%5 mcg NCT01316380 · Phase 3 · registry result, not featured evidence 8.7%5 µg/day NCT00776984 · Phase 3 · registry result, not featured evidence 0%5 µg QD NCT01696071 · Phase 2 · registry result, not featured evidence 1%2.5 µg BID NCT01696071 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%5 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%1.25 mcg NCT01383499 · Phase 2 · registry result, not featured evidence 0%2.5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 1.4%5 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%1.25 µg once daily NCT01233284 · Phase 2 · registry result, not featured evidence · add on 0%2.5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 2.2%5 µg once daily NCT01152450 · Phase 2 · registry result, not featured evidence 0%2.5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%5 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 1.3%1.25 mcg NCT01122680 · Phase 2 · registry result, not featured evidence 0%2100 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%1800 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%900 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 2.9%400 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%200 μg NCT02573155 · Phase 1 · registry result, not featured evidence 0%50 μg NCT02573155 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | 28.8 μg upper respiratory tract infection 6% (placebo 8%) nasopharyngitis 4.7% (placebo 3.4%) sinusitis 4.3% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 show 2 more results14.4 μg nasopharyngitis 6.3% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 2.9% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 7.2 μg nasopharyngitis 7.1% (placebo 3.4%) upper respiratory tract infection 5.8% (placebo 8%) sinusitis 1.7% (placebo 1.3%) NCT03358147 · Phase 2/3 · Asthma · phase 2/3 | 5 µg/dayf asthma 34.6% (placebo 44.6%) peak expiratory flow rate decreased 20.7% (placebo 26.1%) nasopharyngitis 8% (placebo 9%) NCT00772538 · Phase 3 show 28 more resultsurgent care visit due to asthma 1% NCT00565266 · Phase 3 · combination · Asthma · phase 3 2.5 mcg asthma 36.3% (placebo 43.5%) peak expiratory flow rate decreased 23% (placebo 20.6%) nasopharyngitis 11.1% (placebo 9.9%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 34.1% (placebo 43.5%) peak expiratory flow rate decreased 21.5% (placebo 20.6%) respiratory tract infection 9.6% (placebo 12.2%) NCT01634139 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 14.7% (placebo 21.6%) peak expiratory flow rate decreased 11% (placebo 14.9%) nasopharyngitis 4.4% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 5 mcg asthma 16.9% (placebo 21.6%) peak expiratory flow rate decreased 11.5% (placebo 14.9%) nasopharyngitis 4.6% (placebo 8.2%) NCT01634152 · Phase 3 · registry result, not featured evidence · add on 2.5 mcg asthma 21.6% (placebo 23.2%) nasopharyngitis 10.4% (placebo 12.3%) respiratory tract infection viral 8.8% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 5 mcg asthma 16.4% (placebo 23.2%) nasopharyngitis 14.9% (placebo 12.3%) respiratory tract infection viral 7.5% (placebo 8%) NCT01257230 · Phase 3 · registry result, not featured evidence 2.5 μg asthma 11% (placebo 10.4%) peak expiratory flow rate decreased 7.1% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 5 μg asthma 10.8% (placebo 10.4%) peak expiratory flow rate decreased 3.8% (placebo 9.6%) NCT01277523 · Phase 3 · registry result, not featured evidence · add on 2.5 µg once daily nasopharyngitis 44.7% (placebo 42.1%) asthma 29.8% (placebo 36.8%) bronchitis 13.2% (placebo 7%) NCT01340209 · Phase 3 · registry result, not featured evidence 5 µg once daily nasopharyngitis 48.2% (placebo 42.1%) asthma 28.1% (placebo 36.8%) peak expiratory flow rate decreased 15.8% (placebo 21.1%) NCT01340209 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 13.7% (placebo 21.6%) peak expiratory flow rate decreased 10.7% (placebo 19%) nasopharyngitis 6.9% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 22.7% (placebo 21.6%) peak expiratory flow rate decreased 12.9% (placebo 19%) nasopharyngitis 8.3% (placebo 8.2%) NCT01172808 · Phase 3 · registry result, not featured evidence 2.5 mcg once daily asthma 17.1% (placebo 21.3%) nasopharyngitis 12.1% (placebo 10.2%) peak expiratory flow rate decreased 8.2% (placebo 11%) NCT01172821 · Phase 3 · registry result, not featured evidence 5 mcg once daily asthma 19.8% (placebo 21.3%) peak expiratory flow rate decreased 9.9% (placebo 11%) nasopharyngitis 7.5% (placebo 10.2%) NCT01172821 · Phase 3 · registry result, not featured evidence 2.5 mcg asthma 15.6% (placebo 12.3%) peak expiratory flow rate decreased 5.8% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 mcg asthma 11% (placebo 12.3%) peak expiratory flow rate decreased 3.9% (placebo 3.9%) NCT01316380 · Phase 3 · registry result, not featured evidence 5 µg/day asthma 37.9% (placebo 47.9%) peak expiratory flow rate decreased 20.1% (placebo 27.4%) nasopharyngitis 14.6% (placebo 15.4%) NCT00776984 · Phase 3 · registry result, not featured evidence 2.5 µg once daily headache 7.8% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 5 µg once daily headache 5.6% (placebo 4.3%) NCT01152450 · Phase 2 · registry result, not featured evidence 2100 μg nasopharyngitis 40% (placebo 8.3%) bronchitis viral 20% (placebo 0%) feeling hot 20% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 16.7% (placebo 25%) nausea 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 1800 μg headache 9.7% (placebo 25%) chronic obstructive pulmonary disorder 3.2% (placebo 0%) nasopharyngitis 3.2% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 900 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) cough 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 33.3% (placebo 25%) back pain 16.7% (placebo 0%) neck pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 400 μg headache 14.7% (placebo 25%) chronic obstructive pulmonary disorder 5.9% (placebo 0%) nasopharyngitis 2.9% (placebo 8.3%) NCT02573155 · Phase 1 · registry result, not featured evidence 200 μg abscess oral 16.7% (placebo 0%) chest discomfort 16.7% (placebo 8.3%) chest pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence 50 μg headache 50% (placebo 25%) nasopharyngitis 50% (placebo 8.3%) back pain 16.7% (placebo 0%) NCT02573155 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 3 versus Phase 2/3.
- cPopulation context differs: baseline_threshold differs (fev1_pct_predicted>40 versus fev1_pct_predicted<85, fev1_pct_predicted>40); prior_therapy differs (none recorded versus experienced).
- dTreatment context has not been resolved for both arms.
- eAssessment timepoints differ: 14 weeks versus 24 weeks.
- fPopulation comparability has not been reviewed for 39 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Glycopyrronium (PT001)
show 2 more results
show 2 more results
show 2 more results
show 2 more results
Tiotropium bromide
show 30 more results
show 7 more results
show 30 more results
show 28 more results
show 5 more results
show 22 more results
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 18 more results
+ 72 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Glycopyrronium (PT001)'s landscape · Tiotropium bromide's landscape